PZ0355
PF-05085727
≥98% (HPLC)
别名:
4-(1-Azetidinyl)-1-methyl-3-[1-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1H-pyrazolo[3,4-d]pyrimidine, 4-(Azetidin-1-yl)-1-methyl-3-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine
InChI key
SHAVEYUXRBIMLA-UHFFFAOYSA-N
SMILES string
CN(N=C1)C(C2=CC=C(C(F)(F)F)C=C2)=C1C3=NN(C)C4=C3C(N5CCC5)=NC=N4
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
room temp
Quality Level
Biochem/physiol Actions
PF-05085727 is a potent inhibitor against cGMP-dependent phosphodiesterase PDE2 (PDE2A; IC50 = 2.3 nM) with >500-fold selectivity over other PDEs. Its 3-[(18)F]fluoroazetidinyl derivative ([(18)F]PF-05270430) has been successfully applied via i.v. injection as a brain-permeant probe for imaging brain PDE2 in live cynomolgus monkeys by positron emission tomography (PET).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lei Zhang et al.
Journal of medicinal chemistry, 56(11), 4568-4579 (2013-05-09)
To accelerate the discovery of novel small molecule central nervous system (CNS) positron emission tomography (PET) ligands, we aimed to define a property space that would facilitate ligand design and prioritization, thereby providing a higher probability of success for novel
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持